CA2758300C - Checkpoint kinase 1 inhibitors for potentiating dna damaging agents - Google Patents

Checkpoint kinase 1 inhibitors for potentiating dna damaging agents Download PDF

Info

Publication number
CA2758300C
CA2758300C CA2758300A CA2758300A CA2758300C CA 2758300 C CA2758300 C CA 2758300C CA 2758300 A CA2758300 A CA 2758300A CA 2758300 A CA2758300 A CA 2758300A CA 2758300 C CA2758300 C CA 2758300C
Authority
CA
Canada
Prior art keywords
chk1 inhibitor
dna damaging
cancer
damaging agent
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2758300A
Other languages
English (en)
French (fr)
Other versions
CA2758300A1 (en
Inventor
Michael J. Humphries
Shannon L. Winski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CA2758300A1 publication Critical patent/CA2758300A1/en
Application granted granted Critical
Publication of CA2758300C publication Critical patent/CA2758300C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2758300A 2009-04-11 2010-04-09 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents Active CA2758300C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16856309P 2009-04-11 2009-04-11
US61/168,563 2009-04-11
PCT/US2010/030634 WO2010118390A1 (en) 2009-04-11 2010-04-09 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents

Publications (2)

Publication Number Publication Date
CA2758300A1 CA2758300A1 (en) 2010-10-14
CA2758300C true CA2758300C (en) 2017-07-25

Family

ID=42651200

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758300A Active CA2758300C (en) 2009-04-11 2010-04-09 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents

Country Status (15)

Country Link
EP (1) EP2416773B1 (https=)
JP (2) JP5805071B2 (https=)
KR (1) KR101676062B1 (https=)
CN (1) CN102612365B (https=)
AU (1) AU2010233122B2 (https=)
BR (1) BRPI1013920A2 (https=)
CA (1) CA2758300C (https=)
ES (1) ES2608656T3 (https=)
IL (1) IL215709A (https=)
MX (1) MX341368B (https=)
NZ (1) NZ596125A (https=)
RU (1) RU2567044C2 (https=)
SG (3) SG10201900212QA (https=)
WO (1) WO2010118390A1 (https=)
ZA (1) ZA201108273B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711614A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CA2711741A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
US10989719B2 (en) * 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TW202043198A (zh) * 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
KR102285996B1 (ko) * 2019-08-08 2021-08-05 차의과학대학교 산학협력단 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도
WO2021113661A1 (en) 2019-12-05 2021-06-10 Seagen Inc. Amorphous and polymorphic form of a specific chk1 inhibitor
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CN101415417A (zh) * 2006-04-04 2009-04-22 辉瑞产品公司 (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.

Also Published As

Publication number Publication date
KR101676062B1 (ko) 2016-11-14
BRPI1013920A2 (pt) 2016-04-05
ES2608656T3 (es) 2017-04-12
KR20120004523A (ko) 2012-01-12
IL215709A0 (en) 2012-01-31
CN102612365B (zh) 2017-04-12
SG175242A1 (en) 2011-11-28
MX341368B (es) 2016-08-17
RU2011145773A (ru) 2013-05-20
JP2012523435A (ja) 2012-10-04
MX2011010675A (es) 2012-03-16
RU2567044C2 (ru) 2015-10-27
IL215709A (en) 2017-06-29
EP2416773A1 (en) 2012-02-15
NZ596125A (en) 2012-08-31
WO2010118390A1 (en) 2010-10-14
ZA201108273B (en) 2013-07-31
CA2758300A1 (en) 2010-10-14
AU2010233122A1 (en) 2011-11-24
JP2014198741A (ja) 2014-10-23
CN102612365A (zh) 2012-07-25
JP5805071B2 (ja) 2015-11-04
EP2416773B1 (en) 2016-09-28
SG10201900212QA (en) 2019-02-27
AU2010233122B2 (en) 2015-09-17
SG10201404012RA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
CA2758300C (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
US8481557B2 (en) Method of treatment using checkpoint kinase 1 inhibitors
US9370567B2 (en) Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors
CN105849110B (zh) 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法
EP3110509B1 (en) Treating cancer with a combination comprising dinaciclib
AU2008270732B2 (en) Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine
RU2015155283A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
Iratni et al. Sildenafil in combination therapy against cancer: a literature review
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
HK1165273B (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
Raghavendra Camptothecin and analogs: role in anticancer activities
HK1183792A (en) Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
HK1183792B (en) Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150409

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241011